Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of secukinumab plus prednisone taper in relapsing polymyalgia rheumatica
MOH_2024-01-31_013227Phase 3Completed
- Sponsor
- Novartis
- Start
- Jan 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of secukinumab and prednisone in polymyalgia rheumatica (PMR) (3 arms), sponsored by Novartis. Started Jan 2024; status: completed.
02
Drugs
secukinumabprednisone
03
Conditions
polymyalgia rheumatica (PMR)
Beyond the preview
Go deeper on MOH_2024-01-31_013227.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2024-01-31_013227.